Ashley E. Davis is a lead principal at West Front Strategies, a multi-million dollar lobbying firm she co-founded in 2015. A co-founder of the firm she oversees advocacy efforts for the interests of her Fortune 500 clients before the legislative and executive branches of the U.S. government. Clients span a wide variety of industries, including Microsoft, Adobe, Mylan, AETNA, Expedia, Walgreen Co. and Prudential Financial, Inc.
Ashley’s expertise comes from years working in the Executive Branch, where she served in a number of leadership roles. As Special Assistant to National Director (and then Secretary) of Homeland Security Tom Ridge, Ashley directed the daily operations and oversaw the staff at the newly created Office of Homeland Security. Prior to serving as Special Assistant, Ashley was a member of the task force that created the Department of Homeland Security and was involved in creating several government programs, including USA Freedom Corp and several classified programs.
Following her tenure at the White House, Ashley served as a managing principal at Blank Rome and managed the law firm’s strategic alliances with over 20 international public affairs firms.
Ashley holds a Masters of International Business from McDonough School of Business,
Georgetown University and an undergraduate degree from Westminster College, where she is a Member of the Board of Trustees. She sits on several non-profit and corporate Boards such as Turning Point Brands Inc., Vital Voices Global Partnership, the Women’s Democracy Network at the International Republican Institute, the Board of Trustees at Westminster College, Kennedy Center National Symphony Orchestra and the National Museum of Women in the Arts and is a member of Women Corporate Directors.
Day 1: Oct 6, 2020
Day 2: Oct 7, 2020
Day 3: Oct 8, 2020
Keynote Panel Discussion:
Inform your Market Access Strategy with Cross-Border Perspectives on CUSMA, Affordable Drug Prices and Access to Prescription Medicine during Covid-19 and Beyond
One of the consequences of Covid-19 is the problem many people have accessing prescription medication in both Canada and the U.S. because of unemployment and escalating drug costs. Both Canada and the U.S. have taken steps to address rising costs, so far with limited success. CUSMA will also have an impact on access going forward. Gain key insights on:
- The impact CUSMA may have on IP and Canada’s listing on the ‘Watch List’ of the Office of the U.S. Trade Representative
- Canada’s future prospects of gaining access to vaccines for Covid-19
- Progress of drug price containment initiatives of both Canada and the U.S.
Sharpen your North American market access strategies with key insights on cross-border issues